Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$152,077 Mln
P/E Ratio
37.5
P/B Ratio
25.67
Industry P/E
--
Debt to Equity
10.23
ROE
0.68 %
ROCE
5.98 %
Div. Yield
3.39 %
Book Value
10.84
EPS
7.55
CFO
$97,559.00 Mln
EBITDA
$93,864.00 Mln
Net Profit
$64,460.00 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Amgen (AMGN)
| 10.71 | -5.99 | 2.95 | 6.88 | 6.61 | 3.96 | 5.91 |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P 100
| -7.39 | -0.15 | -9.36 | 11.35 | 11.26 | 15.55 | 11.23 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Amgen (AMGN)
| -9.43 | 9.66 | 16.74 | 0.87 | -1.99 | 27.60 | 15.14 |
|
S&P 100
| 29.04 | 30.83 | -22.12 | 27.55 | 19.30 | 29.47 | -5.82 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 193.51 | 340,245.61 | 80.82 | 62.52 | |
| 885.20 | 787,796.72 | 75.11 | 84.41 | |
| 155.91 | 374,629.66 | 17.26 | 29.42 | |
| 84.71 | 209,338.48 | 12.09 | 40.81 |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of... adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. Address: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 Read more
Chairman, CEO & President
Mr. Robert A. Bradway
Chairman, CEO & President
Mr. Robert A. Bradway
Headquarters
Thousand Oaks, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Amgen Inc (AMGN) stood at $ 91,839 Mln as on 31-Dec-24
The share price of Amgen Inc (AMGN) is $288.56 (NASDAQ) as of 29-Apr-2025 16:28 EDT. Amgen Inc (AMGN) has given a return of 6.61% in the last 3 years.
Amgen Inc (AMGN) has a market capitalisation of $ 152,077 Mln as on 29-Apr-2025. As per Value Research classification, it is a Large Cap company.
The P/E ratio of Amgen Inc (AMGN) is 37.50 times as on 29-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Amgen Inc (AMGN) and enter the required number of quantities and click on buy to purchase the shares of Amgen Inc (AMGN).
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. Address: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799
The CEO & director of Mr. Robert A. Bradway. is Amgen Inc (AMGN), and CFO & Sr. VP is Mr. Robert A. Bradway.
There is no promoter pledging in Amgen Inc (AMGN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
74,481
|
|
|
38,015
|
|
|
31,320
|
|
|
19,872
|
| Amgen Inc. (AMGN) | Ratios |
|---|---|
|
Return on equity(%)
|
67.55
|
|
Operating margin(%)
|
23.23
|
|
Net Margin(%)
|
12.24
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of Amgen Inc (AMGN) was $4,090 Mln.
$5.47
(
